BIA
COGT icon

Bell Investment Advisors’s Cogent Biosciences COGT Stock Holding History

Bell Investment Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13
Closed -$462 – 1873
2025
Q4 		$462 Buy
+13
New +$365 ﹤0.01% 1768

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Bell Investment Advisors's COGT Position: Q1 2026 in Review

Bell Investment Advisors sold out of Cogent Biosciences (COGT) in Q1 2026, closing a stake of 13 shares — an estimated $462 sold.

Bell Investment Advisors first reported a position in COGT in Q4 2025 and held it in 1 quarter. The position peaked at $462 in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Bell Investment Advisors reported no remaining Cogent Biosciences position as of Q1 2026 after selling out during the quarter.
  • Bell Investment Advisors sold 13 Cogent Biosciences shares in Q1 2026, an estimated $462.
  • Bell Investment Advisors first reported a position in Cogent Biosciences in Q4 2025 and held it in 1 quarter.
  • Bell Investment Advisors's Cogent Biosciences position peaked at $462 in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Bell Investment Advisors's 13F filing for Q1 2026, filed 17 Apr 2026.